» Articles » PMID: 2342811

Occult Subretinal New Vessels in Age-related Macular Degeneration. Natural History and Early Laser Treatment

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 1990 May 1
PMID 2342811
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Little information is available on the natural history and no data have been published on laser treatment for occult neovascularization in age-related macular degeneration. The visual and angiographic outcomes were analyzed in 156 patients (82 untreated eyes; 81 treated eyes) with occult neovascularization who were followed for 1 to 8 years. Early laser treatment decreased visual acuity to less than 20/200 in 31 of the treated eyes (38%) compared with 20 of the untreated eyes (25%). Three years after the onset of symptoms, 24 treated eyes (29%) and 31 eyes untreated eyes (38%) retained 20/50 visual acuity or better, whereas their respective initial visual acuities were not statistically different. Severe loss of vision (6 or more lines of visual acuity) occurred in 43 treated eyes (53%) and in 33 untreated eyes (40%) at the end of follow-up (range, 12-84 months). A slow and gradual increase of the disciform lesion was demonstrated on fluorescein angiography in 60 untreated eyes, with subfoveal involvement noted in 39 eyes at the end of follow-up. In the treated group, subfoveal involvement occurred in 53 eyes, after a relatively short time (mean, 4 months). Only 28 of the 81 treated eyes had successful anatomic results. These findings suggested that laser treatment of occult neovascularization immediately after the onset of symptoms should not be recommended.

Citing Articles

Impact of optical coherence tomography angiography on the non-invasive diagnosis of neovascular age-related macular degeneration.

Giocanti-Auregan A, Dubois L, Dourmad P, Cohen S Graefes Arch Clin Exp Ophthalmol. 2020; 258(3):537-541.

PMID: 31900638 DOI: 10.1007/s00417-019-04581-y.


Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience.

Ozkaya A, Alkin Z, Togac M, Ahmet S, Perente I, Taskapili M Korean J Ophthalmol. 2017; 31(5):424-430.

PMID: 28913999 PMC: 5636718. DOI: 10.3341/kjo.2016.0125.


Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study.

Elshout M, Webers C, van der Reis M, de Jong-Hesse Y, Schouten J BMC Ophthalmol. 2017; 17(1):120.

PMID: 28693519 PMC: 5504631. DOI: 10.1186/s12886-017-0514-3.


The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting.

Ozkaya A, Alagoz C, Garip R, Alkin Z, Perente I, Yazici A Eye (Lond). 2016; 30(7):958-65.

PMID: 27080484 PMC: 4941072. DOI: 10.1038/eye.2016.71.


Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.

Keane P, De Salvo G, Sim D, Goverdhan S, Agrawal R, Tufail A Clin Ophthalmol. 2015; 9:353-66.

PMID: 25733802 PMC: 4337735. DOI: 10.2147/OPTH.S59012.